Emerging therapeutic opportunities for integrin inhibitors

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology and Medicinal Chemistry
• Cell Biology

Background:

• Integrins are vital cell adhesion and signaling proteins involved in numerous biological processes.
• Approved integrin therapies target αIIbβ3, α4β7/α4β1, and αLβ2 for cardiovascular, inflammatory, and ocular diseases.
• Development of RGD-binding αv integrin inhibitors (e.g., αvβ3) has encountered significant hurdles in oncology, ophthalmology, and osteoporosis.

Purpose of the Study:

• To review historical and current drug discovery efforts for RGD-binding integrins, focusing on αv integrin inhibitors.
• To highlight recent advancements and clinical investigations of novel integrin inhibitors for fibrotic diseases.
• To discuss opportunities for improving integrin drug design by leveraging past trial data and new biological insights.

Main Methods:

• Comprehensive review of biological, clinical, and medicinal chemistry research.
• Analysis of historical and contemporary RGD-binding integrin drug discovery programs.
• Emphasis on small-molecule inhibitors targeting αv integrins.

Main Results:

• Successful targeting of specific integrins has yielded effective treatments for certain diseases.
• Clinical development of αv integrin inhibitors has faced significant challenges.
• Emerging inhibitors targeting αvβ6 and αvβ1 are under investigation for fibrotic conditions like idiopathic pulmonary fibrosis and nonalcoholic steatohepatitis.

Conclusions:

• The field of integrin drug design is at a potential turning point.
• Learning from past clinical trial outcomes and incorporating advances in pharmacology and structural biology are crucial.
• New therapeutic strategies targeting αv integrins, particularly for fibrotic diseases, show promise.